BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) saw a large growth in short interest in October. As of October 31st, there was short interest totalling 86,300 shares, a growth of 72.6% from the October 15th total of 50,000 shares. Based on an average daily volume of 831,300 shares, the days-to-cover ratio is currently 0.1 days. Approximately 3.2% of the company’s stock are short sold.

BioCardia Price Performance

Shares of NASDAQ:BCDA traded down $0.17 during trading on Friday, reaching $1.85. 76,961 shares of the stock were exchanged, compared to its average volume of 297,346. BioCardia has a 1-year low of $1.84 and a 1-year high of $14.40. The stock has a fifty day moving average of $2.59 and a two-hundred day moving average of $3.36. The firm has a market cap of $3.93 million, a price-to-earnings ratio of -0.48 and a beta of 1.28.

BioCardia (NASDAQ:BCDA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). Sell-side analysts forecast that BioCardia will post -5.06 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of BioCardia in a research report on Thursday.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.